Volgende

Automatisch afspelen

Managing Bone Health in Metastatic Breast Cancer

1 Bekeken • 07/03/23
Delen
insluiten
administrator
administrator
abonnees
0

Panelists discuss their preference between denosumab (Xgeva) and zoledronic acid (Zometa), which are both currently approved to help reduce the incidence of skeletal-related events (SREs) in patients with metastatic breast cancer (MBC).

To view more from this discussion, visit http://www.onclive.com/peer-ex....change/MBC-challenge

Laat meer zien
0 Comments sort Sorteer op
Facebook Reacties

Volgende

Automatisch afspelen